GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (NAS:XOMA) » Definitions » Price-to-Free-Cash-Flow

XOMA (XOMA Royalty) Price-to-Free-Cash-Flow : N/A (As of May. 12, 2025)


View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty Price-to-Free-Cash-Flow?

As of today (2025-05-12), XOMA Royalty's share price is $24.79. XOMA Royalty's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.25. Hence, XOMA Royalty's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for XOMA Royalty's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, XOMA Royalty's highest Price-to-Free-Cash-Flow Ratio was 101.23. The lowest was 6.98. And the median was 20.98.

XOMA's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 29.405
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

XOMA Royalty's Free Cash Flow per Share for the three months ended in Dec. 2024 was $-0.25. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.25.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -55.50% per year.

During the past 13 years, XOMA Royalty's highest 3-Year average Free Cash Flow per Share Growth Rate was 59.00% per year. The lowest was -70.00% per year. And the median was 12.70% per year.


XOMA Royalty Price-to-Free-Cash-Flow Historical Data

The historical data trend for XOMA Royalty's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Price-to-Free-Cash-Flow Chart

XOMA Royalty Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.16 - - - -

XOMA Royalty Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of XOMA Royalty's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, XOMA Royalty's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA Royalty's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's Price-to-Free-Cash-Flow falls into.


;
;

XOMA Royalty Price-to-Free-Cash-Flow Calculation

XOMA Royalty's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=24.79/-1.253
=N/A

XOMA Royalty's Share Price of today is $24.79.
XOMA Royalty's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.25.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

XOMA Royalty  (NAS:XOMA) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


XOMA Royalty Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA Royalty Business Description

Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Executives
Bradley Sitko officer: Chief Investment Officer C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Joseph M Limber director ACLARA BIOSCIENCES INC, 1288 PEAR AVE, MOUNTAIN VIEW CA 94043
Thomas M. Burns officer: Chief Financial Officer 2910 SEVENTH STREET, BERKELEY CA 94710
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Owen Hughes director, officer: Interim CEO C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
James R Neal officer: VP Business Development 2910 SEVENTH STREET, BERKELEY CA 94710
Heather L Franklin director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Van Ness W Denman director C/O XOMA LTD, 2910 SEVENTH ST., BERKELEY CA 94710
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta officer: Chief Business Officer 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
John Varian director, officer: Director and CEO ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555